Engineering & Manufacture of Second Generation ADCs: Tools & Techniques - A Webinar hosted by Lonza

First-generation antibody drug conjugates (ADCs) have development challenges, including non-uniform and non-optimized drug-to-antibody ratios (DAR). Lonza’s Site Specific Conjugation (SSC) Vectors, designed for use with Lonza’s proprietary GS Xceed® System, are an effective way to produce conjugation-competent antibodies that have a defined number and location of bioconjugate attachment points. The SSC vectors allow a high degree of control over conjugation site, DAR and conjugation of cargoes in addition to cytotoxins.
In this webinar, we will present a case study based on a model Ab where we will describe how variants containing one or two engineered cysteine residues achieved high levels of homogeneity and DARs of 2 or 4, respectively. In vitro cytotoxicity and in vivo efficacy data will also be presented.
We will also outline a project plan taking an antibody with engineered cysteines to a second-generation ADC. We will highlight the hands-on approach to the adaptation and development of key process steps such as reduction, TFF, reoxidation, conjugation, filtration and formulation. Finally, we’ll provide insight on how to successfully make ADC processes fit for production and scale-up based on Lonza’s extensive ADC development and manufacture expertise.